Particularly, SNPs in the genes encoding estrogen receptors (ESR1 and ESR), in the gene modulating the expression of the enzyme aromatase (CYP19A1) and in CYP11A1 (a gene involved in the steroid pathway) were demonstrated to predict bone density reduction in BC women receiving AIs [38,39,40]. This evidence concerns the gene ESR1 and breast cancer.